Qing Ma PhD
Qing Ma
PhD
Professional Summary:
Research interests areas:
1. Pharmacogenomics of antiretrovirals in patients with HIV-associated neurocognitive disorders
2. Mechanisms of drug-drug interactions in patients with HIV infection
3. Incorporating pharmacokinetics, pharmacodynamics and pharmacogenomics in studying the effects of antiretrovirals on the central nervous system
Education and Training:
- PhD, Loyola University Chicago (2003)
- BS, West China University of Medical Sciences (1995)
Employment:
- Assistant Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2013-present)
- Adjunct Assistant Professor of Pharmacology and Physiology, University of Rochester (2012-present)
- Research Scientist, Translational Pharmacology Research Core, University at Buffalo, New York State Center of Excellence in Bioinformatics and Life Sciences (2006-present)
- Research Assistant Professor, University at Buffalo (2006–2013)
- Fellow, University at Buffalo (2004–2005)
Awards and Honors:
- Research Mentor of the Year (2012)
- Visiting Scholar (2010)
- Visiting Professor (2008)
- Conference Scholarship (2007)
- George McCracken Infectious Disease Fellow (2005)
- George McCracken Infectious Disease Fellow (2004)
- Travel Award (2004)
- Young Investigator Award (2003)
- Graduate Travel Award (2002)
Grants and Sponsored Research:
- June 2012–June 2017
Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDS
NIH
Role: Principal Investigator
$598,880
Journal Articles:
- Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q. Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders. Curr Vasc Pharmacol. 2016.
- Ma Q. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016; 22(2).
- Ma Q. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection PLoS One. 2015; 10(6).
- Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD, Talal AH. Recent advances in management of the HIV/HCV coinfected patient. Future Virol. 2015; 10(8).
- Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother. 2014.
- Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL*, Akinyinka OO, Parikh S. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. The Journal of antimicrobial chemotherapy. 2014; 10(4).
- Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC*, ACTG 5202 Study Team. Outcomes by Sex following Treatment Initiation with Atazanavir plus Ritonavir or Efavirenz with Abacavir/Lamivudine or Tenofovir/Emtricitabine. Clinical Infectious Diseases. 2014; 58(4).
- McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, Difrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD*. Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. The American Journal on Addictions. 2014; 23(2).
- Schifitto G, Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, Difrancesco R, Hochreiter J, Morse GD. CEP-1347 and Atazanavir Pharmacokinetics in HIV-infected Patients. Journal of neurovirology. 2013; 19(3).
- Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. J Neurovirol. 2013; 19(3).
- Mikula J, Sawyer JR, Ma Q, Sulaiman AS, Hsiao CB, Morse GD. Comparative effectiveness of darunavir 1,200 mg daily and approved dosing strategies for protease inhibitor-experienced patients. AIDS Research and Treatment. 2013.
- Morse ED; Maartens G; Maponga C; Ma Q. Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Research and Treatment. 2012; 2012.
- Morse GD*, Maartens G, Maponga CC, Ma Q. Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Research and Treatment. 2012; 2012.
- Hochreiter J, McCance-Katz EF, Lapham J, Ma Q, Morse GD*. Disulfram Metabolite S-Methyl-N, N-Diethylthiocarbamate Quantitation in Human Plasma With Reverse Phase Ultra Performance Liquid Chromatography and Mass Spectrometry. Journal of Chromatography B Analyt Technol Biomed Sci. 2012; 894.
- Nanzigu S, Eriksen J, Makumbi F, Lanke S, Mahindi M, Kiguba R, Beck O, Ma Q, Morse GD, Gustafsson LL, Waako P*. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz amon HIV-infected Ugandans.. HIV Medicine. 2012; 13(4).
- Mudzviti T, Maponga CC, Khoza S, Ma Q, Morse GD*. The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe.. AIDS Res Treat. 2012; 2012.
- Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT*. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012.
- Gruber VA, Rainey PM, Moody DE, Morse GD, Ma Q, Prathikanti S, Pade PA, Alvanzo AA, McCance-Katz EF*. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Journal of Clinical Infectious Diseases. 2012; 54(3).
- Venuto CS; McGarry A; Ma Q; Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease.. Movement disorders. 2012; 27.
- Wang J; Kou H; Fu Q; Han Y; Ma Q; Li T. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.. PLoS One. 2011; 6.
- Ma Q, Zingman BS, Luque A, Fischl MA, Gripshover B, Venuto C, DiFrancesco R, Forrest A, Morse GD*. Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals with Active Substance Related Disorders. Ther Drug Monit. 2011; 33(3).
- Crutchley RD, Ma Q, Sulaiman A, Hochreiter J, Morse GD*. Within Patient Atazanavir Trough Concentration Monitoring in HIV-1 Infected Patients. J Pharm Pract. 2011; 24(2).
- Zhang L; Ma Q; Zhou H. Host proteome research in HIV infection.. 2010.
- Liu X; Ma Q; Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy.. 2010.
- Zhang R; Ma Q; Lu H. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.. 2009.
- Lakhman SS; Ma Q; Morse ED. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009; 10.
- McCabe SM; Ma Q; Slish J; Catanzaro LM; Sheth N; DiCenzo R; Morse ED. Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.. Clin Pharmacokinet. 2008; 47.
- Cheang KI; Ma Q. Research in women and special populations. Pharmacotherapy. 2008; 28.
- Ma Q; Forrest A; Rosenkranz SL; Para MF; Yarasheski KE; Reichman RC; Morse ED. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos. 2008; 29.
- McCabe SM; Ma Q; Slish J; Catanzaro LM; Sheth N; DiCenzo R; Morse ED. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clinical Pharmacokinetics. 2008; 47.
- Ma Q; DiFrancesco R; Morse ED; Slish J; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau DA; Boston N; Catanzaro LM. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit. 2007; 29.
- Ma Q; Brazeau DA; Forrest A; Morse ED. Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics. 2007; 8.
- Maponga C; Ma Q; Slish J; Morse ED. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med. 2007; 15.
- McCabe SM; Smith PF; Ma Q; Morse ED. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007; 3.
- Ma Q; Forrest A; Morse ED; Brazeau DA; Zingman BS; Reichman RC; Fischl MA; Gripshover BM; Venuto CS; Slish J; DiFrancesco R. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007; 8.
- Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006; 12(9).
- Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol. 2005; 1(3).
Abstracts:
- Mudzviti T; Maponga C; Khoza S; Tagwireyi D; Ma Q; Morse ED. Adverse Drug Reactions During Antiretroviral Therapy in Zimbabwe. 37th Annual International Conference on Global Health. 2010.
- Maponga C; DiFrancesco R; Tooley KM; Jaravani P; Ma Q; Morse ED. Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research In Southern African Countries. 18th International AIDS Conference (AIDS 2010). 2010.
- Venuto C; Ma Q; Morse ED. Effects of CYP2B6 single nucleotide polymorphism (SNPs) and substance abude on efavirenz (EFV) pharmacokinetics. UB Celebration of Academic Excellence. 2010.
- Ma Q; Tooley KM; Welliver R; Condino D; Lliguicota F; Maponga C; DiFrancesco R; Morse ED; Sulaimen A; Felton C; Sawyer JR; Mudzviti T; Hsiao CB; Walshe K; Gbadamosi F; Sayidine F. Developing an International Health Information Technology Network for HIV Medication Management Research. NY HIV Research Centers Consortium. 2010.
- Venuto C; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman RC; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics. ICAAC Conference. 2009.
- Acheampong F; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Relationship between CYP3A5 Nucleotide Polymorphisms and Protease Inhibitor Trough Concentrations in HIV+ Patients during Therapeutic Drug Monitoring. ICAAC Conference. 2009.
- Fehintola F; Ma Q; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A; Morse ED. Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals. ICAAC Conference. 2009.
- Ma Q; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman RC; Morse ED; A. Optimal multidrug PK and sampling strategies (OSS) for efavirenz and indinavir. 2005 Annual Meeting of the American Society of Clinical Pharmacology & Therapeutics. 2005.
- Zack J; A; Forrest A; Ma Q; Rosenkranz S; Para MF; Adams E; Yaresheski K; Reichman RC; Morse ED. Optimal Sparse Pharmacokinetic Sampling Strategies for Multi-Drug Antiretroviral Regimens. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.
Professional Memberships:
- International AIDS Society (2006)
- American Society of Microbiology (2004)
- Society of Infectious Diseases Pharmacists (2004)
- American Society for Clinical Pharmacology and Therapeutics; Award Committee Member, Education Committee Member (2001)
- American Society for Clinical Pharmacology and Therapeutics (2000–present)
- American Pharmacist Association (1999)
Presentations:
- "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference (IAS AIDS 2012), IAS AIDS (2012)
- "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" ACTG Conference, ACTG (2012)
- "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference (2012)
- "Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
- "Tenofovir plasma pharmacokinetics in AIDS Clinical Trials Group Study A5202." XIX International AIDS Conference (2012)
- "Comparison of modeled and non-modeled clearances for efeavirenz" Translational Science 2012 (2012)
- "Pharmacogenomics of CYP3A: Considerations for HIV Treatment" 5th Health Disparities Conference, Xavier University of Louisiana (2012)
- "A Physiological Pharmacokinetic Model Characterizes Efavirenz Metabolic Induction in HIV-Infected Ugandan Patients" 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2011)
- "Pharmacokinetics of efavirenz among HIV infected Ugandans" 12th International Workshop on Clinical Pharmacology of HIV Thearpy (2011)
- "Establishing A Health Information Technology Network for HIV/TB Medication Management Research" DCFAR 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
- "Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients" 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2010)
- "Pharmaceutical Safety Initiative: Enhancing Patient Safety with Information Technology and Biomedical Informatics" Pharmacy Safety Forum, New York Department of Health - Patient Safety Center (2010)
- "Developing an International Health Information Technology Network for HIV Medication Management Research" NY HIV Research Centers Consortium 2010 Scientific Conference (2010)
- "Update on pharmacotherapy for pediatric HIV infection" 13th Asian Pacific Congress of Pediatrics (2009)
- "Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics" 49th ICAAC, ASM (2009)
- "Inter-individual variability of atazanavir plasma concentrations in HIV patients" 49th ICAAC, ASM (2009)
- "Relationship between CYP3A5 single nucleotide polymorphisms and protease inhibitor trough concentrations in HIV+ patients during therapeutic drug monitoring" 49th ICAAC, ASM (2009)
- "Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV infected individuals" 49th ICAAC, ASM (2009)
- "Comparison of antiretroviral pharmacokinetics and clinical monitoring parameters in HIV-infected patients with and without substance abuse" 16th Conference on Retroviruses and Opportunistic Infections (2009)
- "Clinical and Translational Pharmacogenomics: Integrating a Seminar Program with UndergraduatePharmacogenomics Research" ACCP Annual Meeting, American College of Clinical Pharmacy (2008)
- "Determining the rate, nature and predictors of adverse drug reactions associated with the use of highly active antiretroviral therapy (HAART) in a resource limited setting (Zimbabwe)" The IXth World Conference on Clinical Pharmacology and Therapeutics (2008)
- "Effect of CYP3A5 polymorphisms on atazanavir and lopinavir trough concentrations in HIV-infected substance abusers" 9th International Workshop on Clinical Pharmacology of HIV Therapy (2008)
- "An Appropriate Structural and Population Pharmacokinetic (PK) Model for Atazanavir (ATV)" ICAAC (2007)
- "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" ICAAC (2007)
- "Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Users and Non-substance Users Receiving HIV-1 Protease Inhibitors" CROI 2007 (2007)
- "CYP3A5 polymorphisms in HIV-infected substance users and nonusers during therapeutic drug monitoring" 49th Annual Meeting of ICAAC (2006)
- "MDR1 Polymorphisms, Therapeutic Drug Monitoring, Protease Inhibitors" CROI (2006)
- "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" 45th Annual ICAAC (2005)
Service Activities:
- Neurology Collaborative Science Group Scientific Committee; AIDS Clinical Trip Group; Member (2012)
- Chinese Clinical Pharmacy Collaboration; Communication between Chinese pharmacy schools and UB, development of MOU; Coordinator (2011)
- Education Committee; American Society for Clinical Pharmacology and Therapeutics Education Committee Award Committee; Other (2008)